BACKGROUND: In 2007, Malawi replaced the first-line medication for uncomplicated malaria, sulfadoxine-pyrimethamine-a single-dose regimen-with artemether-lumefantrine (AL)-a 6-dose, 3-day regimen. Because of concerns about the complex dosing schedule, we assessed patient adherence to AL 2 years after routine implementation. METHODS: Adults and children with uncomplicated malaria were recruited at 3 health centers. We conducted both pill counts and in-home interviews on medication consumption 72 hours after patients received AL. Complete adherence was defined as correctly taking all 6 AL doses, as assessed by pill count and dose recall. We used logistic regression to identify factors associated with complete adherence. RESULTS: Of 386 patients, 65% were completely adherent. Patients were significantly more likely to be completely adherent if they received their first dose of AL as directly observed therapy at the health center (odds ratio [OR], 2.4; P < .01), received instructions using the medication package as a visual aid (OR, 2.5; P = .02), and preferred AL over other antimalarials (OR, 2.7; P < .001). In contrast, children <5 years of age were significantly less likely to be adherent (OR, 0.5; P = .05). CONCLUSIONS: Adherence to AL treatment for uncomplicated malaria was moderate, and children, who are the most likely to die of malaria, were less adherent than adults. Efforts to improve adherence should be focused on this vulnerable group. Interventions including the introduction of child-friendly antimalarial formulations, direct observation of the first dose, use of the AL package as a visual aid for instructions, and enhancing patient preference for AL could potentially increase AL adherence and overall effectiveness.
BACKGROUND: In 2007, Malawi replaced the first-line medication for uncomplicated malaria, sulfadoxine-pyrimethamine-a single-dose regimen-with artemether-lumefantrine (AL)-a 6-dose, 3-day regimen. Because of concerns about the complex dosing schedule, we assessed patient adherence to AL 2 years after routine implementation. METHODS: Adults and children with uncomplicated malaria were recruited at 3 health centers. We conducted both pill counts and in-home interviews on medication consumption 72 hours after patients received AL. Complete adherence was defined as correctly taking all 6 AL doses, as assessed by pill count and dose recall. We used logistic regression to identify factors associated with complete adherence. RESULTS: Of 386 patients, 65% were completely adherent. Patients were significantly more likely to be completely adherent if they received their first dose of AL as directly observed therapy at the health center (odds ratio [OR], 2.4; P < .01), received instructions using the medication package as a visual aid (OR, 2.5; P = .02), and preferred AL over other antimalarials (OR, 2.7; P < .001). In contrast, children <5 years of age were significantly less likely to be adherent (OR, 0.5; P = .05). CONCLUSIONS: Adherence to AL treatment for uncomplicated malaria was moderate, and children, who are the most likely to die of malaria, were less adherent than adults. Efforts to improve adherence should be focused on this vulnerable group. Interventions including the introduction of child-friendly antimalarial formulations, direct observation of the first dose, use of the AL package as a visual aid for instructions, and enhancing patient preference for AL could potentially increase AL adherence and overall effectiveness.
Authors: Raymond K Sudoi; Sophie Githinji; Andrew Nyandigisi; Alex Muturi; Robert W Snow; Dejan Zurovac Journal: Malar J Date: 2012-02-08 Impact factor: 2.979
Authors: Laura C Steinhardt; Don P Mathanga; Dyson Mwandama; Humphreys Nsona; Dubulao Moyo; Austin Gumbo; Miwako Kobayashi; Ruth Namuyinga; Monica P Shah; Andy Bauleni; Peter Troell; Dejan Zurovac; Alexander K Rowe Journal: Am J Trop Med Hyg Date: 2019-02 Impact factor: 2.345
Authors: Georgia R Gore-Langton; Nfornuh Alenwi; James Mungai; Nahashon I Erupe; Katie Eves; Francis Njoroge Kimwana; David Soti; Willis Akhwale; Farah A Hassan; Elizabeth Juma; Richard Allan Journal: Malar J Date: 2015-03-24 Impact factor: 2.979
Authors: Ahmad M Yakasai; Muhammad Hamza; Mahmood M Dalhat; Musa Bello; Muktar A Gadanya; Zuwaira M Yaqub; Daiyabu A Ibrahim; Fatimah Hassan-Hanga Journal: J Trop Med Date: 2015-05-28
Authors: Sarah V Kedenge; Beth P Kangwana; Evelyn W Waweru; Andrew J Nyandigisi; Jayesh Pandit; Simon J Brooker; Robert W Snow; Catherine A Goodman Journal: PLoS One Date: 2013-01-14 Impact factor: 3.240